Phase 3 data of Sarecycline, a once-daily, oral narrow-spectrum antibiotic with anti-inflammatory properties developed by Paratek (PRTK) in conjunction with Allergan (AGN) for Severe acne vulgaris due Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?